Will FCX Benefit From Tariffs?
Freeport-McMoRan (NYSE:FCX) is among the world’s largest producers of copper…
Buy
59
LAB Quote, Financials, Valuation and Earnings
Last price:
$1.24
Seasonality move
:
1.41%
Day range:
$1.21 - $1.26
52-week range:
$0.92 - $2.41
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
2.69x
P/B ratio:
0.97x
Volume:
1.4M
Avg. volume:
2.3M
1-year change:
-45.85%
Market cap:
$440.7M
Revenue:
$174.4M
EPS (TTM):
-$0.35
Analysts' Opinion
-
Consensus RatingStandard BioTools has received a consensus rating of Buy. The company's average rating is a Buy based on 2 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $2.38, Standard BioTools has an estimated upside of 94.67% from its current price of $1.24.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $2.25 representing -84.43% downside risk from its current price of $1.24.
Fair Value
-
According to the consensus of 3 analysts, Standard BioTools has 94.67% upside to fair value with a price target of $2.38 per share.
LAB vs. S&P 500
-
Over the past 5 trading days, Standard BioTools has underperformed the S&P 500 by -5.6% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Standard BioTools does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Standard BioTools revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Standard BioTools reported revenues of $40.8M.
Earnings Growth
-
Standard BioTools has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Standard BioTools reported earnings per share of -$0.07.
Enterprise value:
183M
EV / Invested capital:
--
Price / LTM sales:
2.69x
EV / EBIT:
--
EV / Revenue:
1.08x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-1.48x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$79.8M
Return On Assets:
-19.76%
Net Income Margin (TTM):
-78.24%
Return On Equity:
-26.52%
Return On Invested Capital:
-24.87%
Operating Margin:
-74.26%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | $96.6M | $126.8M | $169.7M | $45.5M | $40.8M | |
| Gross Profit | $37.1M | $62.3M | $79.8M | $24.2M | $19.7M | |
| Operating Income | -$95.8M | -$86.3M | -$126.3M | -$38.7M | -$30.3M | |
| EBITDA | -$113.5M | -$68.5M | -$106.6M | -$25.8M | -$22M | |
| Diluted EPS | -$1.66 | -$1.01 | -$0.35 | -$0.27 | -$0.07 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $96.3M | $73.2M | $194.9M | $547.6M | $344M | |
| Total Assets | $305.2M | $271.9M | $371.7M | $777.7M | $579.6M | |
| Current Liabilities | $53.5M | $47.2M | $43.8M | $121.6M | $56.2M | |
| Total Liabilities | $182.3M | $249.8M | $468.8M | $200.4M | $125M | |
| Total Equity | $122.9M | $22.1M | -$97.2M | $577.3M | $454.6M | |
| Total Debt | $53.8M | $100M | $65.1M | $55M | $299K | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$82.3M | -$97.3M | -$111.3M | -$62.5M | -$30.3M | |
| Cash From Investing | -$44.1M | $295.2M | $59.7M | $318.1M | $14.6M | |
| Cash From Financing | $210.1M | -$24M | -$82.9M | -$19.7M | -$46K | |
| Free Cash Flow | -$86.2M | -$99.9M | -$123.9M | -$63.3M | -$35.3M | |
LAB
Sector
Market Cap
$440.7M
$34.5M
Price % of 52-Week High
50.62%
49.05%
Dividend Yield
0%
0%
Shareholder Yield
10.28%
-1.01%
1-Year Price Total Return
-42.18%
-35.15%
Beta (5-Year)
1.543
0.615
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$1.29
200-day SMA
Sell
Level
$1.46
Bollinger Bands (100)
Buy
Level
1.05 - 1.23
Chaikin Money Flow
Sell
Level
-1.6M
20-day SMA
Sell
Level
$1.24
Relative Strength Index (RSI14)
Buy
Level
51.82
ADX Line
Sell
Level
19.01
Williams %R
Neutral
Level
-73.0769
50-day SMA
Buy
Level
$1.13
MACD (12, 26)
Buy
Level
0.35
25-day Aroon Oscillator
Buy
Level
12
On Balance Volume
Sell
Level
-513.8K
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (0.273)
Sell
CA Score
(Annual)
Level (-2.3273)
Sell
Beneish M-Score
(Annual)
Level (-1.7026)
Buy
Momentum Score
Level (2)
Sell
Ohlson Score
Level (0.5653)
Buy
Piotroski F Score
(Annual)
Level (4)
Sell
Quality Ratio Score
Level (3)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. Its segments include Proteomics and Genomics. It generates maximum revenue from the Proteomics segment. Geographically, it derives a majority of its revenue from the Americas.
Stock Forecast FAQ
In the current month, LAB has received 2 Buy ratings 1 Hold ratings, and 0 Sell ratings. The LAB average analyst price target in the past 3 months is $2.38.
-
Where Will Standard BioTools Stock Be In 1 Year?
According to analysts, the consensus estimate is that Standard BioTools share price will rise to $2.38 per share over the next 12 months.
-
What Do Analysts Say About Standard BioTools?
Analysts are divided on their view about Standard BioTools share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Standard BioTools is a Sell and believe this share price will drop from its current level to $2.25.
-
What Is Standard BioTools's Price Target?
The price target for Standard BioTools over the next 1-year time period is forecast to be $2.38 according to 3 Wall Street analysts, 2 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is LAB A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Standard BioTools is a Buy. 2 of 3 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of LAB?
You can purchase shares of Standard BioTools via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Standard BioTools shares.
-
What Is The Standard BioTools Share Price Today?
Standard BioTools was last trading at $1.24 per share. This represents the most recent stock quote for Standard BioTools. Yesterday, Standard BioTools closed at $1.24 per share.
-
How To Buy Standard BioTools Stock Online?
In order to purchase Standard BioTools stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Can Levi Stock Double?
Levi Strauss (NYSE:LEVI) is among the oldest clothing brands in…
How High Can SharkNinja Stock Go?
If you know popular consumer appliance brands Shark and Ninja,…
Stock Ideas
Buy
70
Is NVDA Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 58x
Buy
62
Is MSFT Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 43x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 35x
Alerts
Buy
89
EXOD alert for Jul 17
Exodus Movement [EXOD] is up 21.96% over the past day.
Buy
82
SBET alert for Jul 17
SharpLink Gaming [SBET] is up 28.58% over the past day.
Buy
60
U alert for Jul 17
Unity Software [U] is up 14.38% over the past day.
